{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:38:55Z","timestamp":1771994335106,"version":"3.50.1"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.2169\/internalmedicine.4871-24","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T18:14:39Z","timestamp":1741976079000},"page":"2631-2636","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab as an Effective Treatment for New-onset Evans Syndrome and Systemic Lupus Erythematosus with Lupus Nephritis"],"prefix":"10.2169","volume":"64","author":[{"given":"Koki","family":"Matsushita","sequence":"first","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"},{"name":"Department of Nephrology, NHO Kumamoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Nagayoshi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHO Kumamoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHO Kumamoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Kajiwara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHO Kumamoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kakizoe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, NHO Kumamoto Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukimasa","family":"Kohda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mukoyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Omuta Tenryo Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenia purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med 87: 48-65, 1951.","DOI":"10.1001\/archinte.1951.03810010058005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hansen DL, M\u00f6ller S, Andersen K, Gaist D, Frederiksen H. Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort. Am J Hematol 94: 1081-1090, 2019.","DOI":"10.1002\/ajh.25574"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Michel M. Adult Evans' syndrome. Hematol Oncol Clin North Am 36: 381-392, 2022.","DOI":"10.1016\/j.hoc.2021.12.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Serris A, Amoura Z, Canou\u00ef-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol 93: 424-429, 2018.","DOI":"10.1002\/ajh.24999"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fattizzo B, Michel M, Giannotta JA, et al. Evans syndrome in adults: an observational multicenter study. Blood Adv 24: 5468-5478, 2021.","DOI":"10.1182\/bloodadvances.2021005610"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 114: 3167-3172, 2009.","DOI":"10.1182\/blood-2009-04-215368"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3: 3780-3817, 2019.","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jager U, Barcellini W, Broom CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus. Blood Rev 41: 100648, 2020.","DOI":"10.1016\/j.blre.2019.100648"},{"key":"9","unstructured":"9. Aringer M, Costenbader K, Daikh D, et al. 2019 European league against rheumatism\/Amerian college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71: 1400-1412, 2019."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Velo-Garc\u00eda A, Castro SG, Isenberg DA. The diagnosis and management of haematologic manifestations of lupus. J Autoimmun 74: 139-160, 2016.","DOI":"10.1016\/j.jaut.2016.07.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med 2: e000078, 2015.","DOI":"10.1136\/lupus-2014-000078"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rhematology 42: 230-234, 2003.","DOI":"10.1093\/rheumatology\/keg069"},{"key":"13","first-page":"466","volume":"84","author":"J Arvieux","year":"1991","unstructured":"13. Arvieux J, Roussel B, Ponard D, Colomb MG. Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation. Clin Exp Immunol 84: 466-471, 1991.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans' syndrome: from diagnosis to treatment. J Clin Med 9: 3851, 2020.","DOI":"10.3390\/jcm9123851"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 121: 1976-1981, 2013.","DOI":"10.1182\/blood-2012-09-455691"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115: 2755-2762, 2010.","DOI":"10.1182\/blood-2009-07-229815"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 93: 91-98, 2011.","DOI":"10.1007\/s12185-010-0753-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in autoimmune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev 14: 304-313, 2015.","DOI":"10.1016\/j.autrev.2014.11.014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-bind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol 92: 23-27, 2017.","DOI":"10.1002\/ajh.24570"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 119: 3691-3697, 2012.","DOI":"10.1182\/blood-2011-06-363556"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dhakal S, Neupane S, Mandal A, et al. Evans syndrome: a case report. J Nepal Med Assoc 60: 482-484, 2022.","DOI":"10.31729\/jnma.7421"},{"key":"22","unstructured":"22. Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc 60: 64-65, 2010."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226, 2012.","DOI":"10.1002\/art.34359"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222-233, 2010.","DOI":"10.1002\/art.27233"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tanaka Y, Nakayamada S, Yamaoka K, Ohmura K, Yasuda S. Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan. Mod Rheumatol 33: 145-153, 2023.","DOI":"10.1093\/mr\/roac007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fattizo B, Marchetti M, Mechel M, et al. Diagnosis and management of Evans syndrome in adults: first consensus recommendations. Lancet Haematol 11: e617-e628, 2024.","DOI":"10.1016\/S2352-3026(24)00144-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Palvia A, Damera AR, Magar S, Nandi AR, Goyal M. Diagnostic and therapeutic strategies in Evans syndrome: a case report and literature review. Cureus 16: e64866, 2024.","DOI":"10.7759\/cureus.64866"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/17\/64_4871-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:25:14Z","timestamp":1757129114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/17\/64_4871-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":27,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4871-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"4871-24"}}